PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease
May 25, 2021
Ryan Allway May 25th, 2021 Psychedelics TORONTO, May 25, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that it has filed an application with the U.S. Food and Drug Administration (“FDA”) to receive... Read more
